SRR1475803
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.479
- INFLAMMATORY_RESPONSE+0.340
- ANGIOGENESIS+0.273
- PANCREAS_BETA_CELLS+0.272
- APICAL_SURFACE+0.266
- KRAS_SIGNALING_UP+0.257
- ALLOGRAFT_REJECTION+0.251
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.244
- IL6_JAK_STAT3_SIGNALING+0.240
- COAGULATION+0.208
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.720
- MYC_TARGETS_V1-0.681
- MYC_TARGETS_V2-0.569
- UNFOLDED_PROTEIN_RESPONSE-0.565
- DNA_REPAIR-0.560
- PROTEIN_SECRETION-0.534
- ADIPOGENESIS-0.511
- MTORC1_SIGNALING-0.498
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.497
- FATTY_ACID_METABOLISM-0.431
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1443979 | GTEX | — | 0.978 |
| 2 | SRR1485167 | GTEX | — | 0.976 |
| 3 | SRR1487295 | GTEX | — | 0.976 |
| 4 | SRR1334440 | GTEX | — | 0.974 |
| 5 | SRR1338301 | GTEX | — | 0.974 |
| 6 | SRR1473590 | GTEX | — | 0.967 |
| 7 | SRR615515 | GTEX | — | 0.967 |
| 8 | SRR1322419 | GTEX | — | 0.965 |
| 9 | SRR1440246 | GTEX | — | 0.965 |
| 10 | SRR1337431 | GTEX | — | 0.965 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.479 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.273 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.272 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.266 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.257 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.251 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.244 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| COAGULATION | 0.208 | Binimetinib | — uncovered |
| SPERMATOGENESIS | 0.167 | Inavolisib | — uncovered |
| MYOGENESIS | 0.127 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.126 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.056 | Idelalisib | — uncovered |
| COMPLEMENT | 0.048 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.047 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.040 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.018 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.014 | Inavolisib | — uncovered |